skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Material Type:
Artigo 		Adicionar ao Meu Espaço

HER2+ breast cancer treatment and cardiotoxicity: monitoring and management

Jerusalem, Guy ; Lancellotti, Patrizio ; Kim, Sung-Bae

Breast cancer research and treatment, 2019-09, Vol.177 (2), p.237-250 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por
2
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

Pottier, Charles ; Fresnais, Margaux ; Gilon, Marie ; Jérusalem, Guy ; Longuespée, Rémi ; Sounni, Nor Eddine

Cancers, 2020-03, Vol.12 (3), p.731 [Periódico revisado por pares]

Switzerland: MDPI AG

Texto completo disponível

Citações Citado por
3
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Slamon, Dennis J ; Neven, Patrick ; Chia, Stephen ; Fasching, Peter A ; De Laurentiis, Michelino ; Im, Seock-Ah ; Petrakova, Katarina ; Bianchi, Giulia V ; Esteva, Francisco J ; Martín, Miguel ; Nusch, Arnd ; Sonke, Gabe S ; De la Cruz-Merino, Luis ; Beck, J. Thaddeus ; Pivot, Xavier ; Sondhi, Manu ; Wang, Yingbo ; Chakravartty, Arunava ; Rodriguez-Lorenc, Karen ; Taran, Tetiana ; Jerusalem, Guy

The New England journal of medicine, 2020-02, Vol.382 (6), p.514-524 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por
4
Triple-negative breast cancer: treatment challenges and solutions
Triple-negative breast cancer: treatment challenges and solutions
Material Type:
Artigo 		Adicionar ao Meu Espaço

Triple-negative breast cancer: treatment challenges and solutions

Collignon, Joëlle ; Lousberg, Laurence ; Schroeder, Hélène ; Jerusalem, Guy

Breast cancer targets and therapy, 2016-01, Vol.8 (Issue 1), p.93-107 [Periódico revisado por pares]

New Zealand: Dove Medical Press Limited

Texto completo disponível

Citações Citado por
5
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

Slamon, Dennis J ; Neven, Patrick ; Chia, Stephen ; Fasching, Peter A ; De Laurentiis, Michelino ; Im, Seock-Ah ; Petrakova, Katarina ; Bianchi, Giulia Val ; Esteva, Francisco J ; Martín, Miguel ; Nusch, Arnd ; Sonke, Gabe S ; De la Cruz-Merino, Luis ; Beck, J Thaddeus ; Pivot, Xavier ; Vidam, Gena ; Wang, Yingbo ; Rodriguez Lorenc, Karen ; Miller, Michelle ; Taran, Tetiana ; Jerusalem, Guy

Journal of clinical oncology, 2018-08, Vol.36 (24), p.2465-2472 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
6
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

Awada, Ahmad, Dr Prof ; Garcia, Agustin A, MD ; Chan, Stephen, MD ; Jerusalem, Guy H M, Prof ; Coleman, Robert E, Prof ; Huizing, Manon T, Prof ; Mehdi, Aminder, MD ; O'Reilly, Sue M, MD ; Hamm, John T, MD ; Barrett-Lee, Peter J, Prof ; Cocquyt, Veronique, Prof ; Sideras, Kostandinos, MD ; Young, David E, MD ; Zhao, Carol, MS ; Chia, Yen Lin, PhD ; Hoch, Ute, PhD ; Hannah, Alison L, MD ; Perez, Edith A, Prof

The lancet oncology, 2013-11, Vol.14 (12), p.1216-1225 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Codon-specific translation reprogramming promotes resistance to targeted therapy
Codon-specific translation reprogramming promotes resistance to targeted therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Codon-specific translation reprogramming promotes resistance to targeted therapy

Rapino, Francesca ; Delaunay, Sylvain ; Rambow, Florian ; Zhou, Zhaoli ; Tharun, Lars ; De Tullio, Pascal ; Sin, Olga ; Shostak, Kateryna ; Schmitz, Sebastian ; Piepers, Jolanda ; Ghesquière, Bart ; Karim, Latifa ; Charloteaux, Benoit ; Jamart, Diane ; Florin, Alexandra ; Lambert, Charles ; Rorive, Andrée ; Jerusalem, Guy ; Leucci, Eleonora ; Dewaele, Michael ; Vooijs, Marc ; Leidel, Sebastian A ; Georges, Michel ; Voz, Marianne ; Peers, Bernard ; Büttner, Reinhard ; Marine, Jean-Christophe ; Chariot, Alain ; Close, Pierre

Nature (London), 2018-06, Vol.558 (7711), p.605-609 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
8
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
Material Type:
Artigo 		Adicionar ao Meu Espaço

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

André, Fabrice ; Hurvitz, Sara ; Fasolo, Angelica ; Tseng, Ling-Ming ; Jerusalem, Guy ; Wilks, Sharon ; O'Regan, Ruth ; Isaacs, Claudine ; Toi, Masakazu ; Burris, Howard ; He, Wei ; Robinson, Douglas ; Riester, Markus ; Taran, Tetiana ; Chen, David ; Slamon, Dennis

Journal of clinical oncology, 2016-06, Vol.34 (18), p.2115-2124 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
9
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

Giuliano, Mario, MD ; Schettini, Francesco, MD ; Rognoni, Carla, PhD ; Milani, Manuela, MD ; Jerusalem, Guy, Prof ; Bachelot, Thomas, MD ; De Laurentiis, Michelino, MD ; Thomas, Guglielmo, MD ; De Placido, Pietro, MD ; Arpino, Grazia, MD ; De Placido, Sabino, Prof ; Cristofanilli, Massimo, MD ; Giordano, Antonio, MD ; Puglisi, Fabio, MD ; Pistilli, Barbara, MD ; Prat, Aleix, MD ; Del Mastro, Lucia, MD ; Venturini, Sergio, PhD ; Generali, Daniele, MD

The lancet oncology, 2019-10, Vol.20 (10), p.1360-1369 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

André, Fabrice, Prof ; O'Regan, Ruth, Prof ; Ozguroglu, Mustafa, Prof ; Toi, Masakazu, Prof ; Xu, Binghe, Prof ; Jerusalem, Guy, Prof ; Masuda, Norikazu, MD ; Wilks, Sharon, MD ; Arena, Francis, MD ; Isaacs, Claudine, Prof ; Yap, Yoon-Sim, MD ; Papai, Zsuzsanna, MD ; Lang, Istvan, Prof ; Armstrong, Anne, MD ; Lerzo, Guillermo, MD ; White, Michelle, MD ; Shen, Kunwei, Prof ; Litton, Jennifer, MD ; Chen, David, PhD ; Zhang, Yufen, PhD ; Ali, Shyanne ; Taran, Tetiana, MD ; Gianni, Luca, Dr

The lancet oncology, 2014-05, Vol.15 (6), p.580-591 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (423)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (309)
  2. Web Resources  (122)
  3. Conjunto de Dados  (9)
  4. Outros  (7)
  5. Book Chapters  (4)
  6. Recursos Textuais  (4)
  7. magazinearticle  (4)
  8. Imagens  (3)
  9. Livros  (1)
  10. Anais de Congresso  (1)
  11. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2001  (14)
  2. 2001Até2006  (44)
  3. 2007Até2012  (55)
  4. 2013Até2019  (205)
  5. Após 2019  (148)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (389)
  2. Francês  (74)
  3. Japonês  (18)
  4. Russo  (3)
  5. Italiano  (1)
  6. Norueguês  (1)
  7. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.